Cabotegravir plus rilpivirine given by injection every 8 weeks appeared to be a promising new therapeutic option for people living with HIV at the 48-week mark in the ATLAS-2M trial.
Reuters Health Information

Cabotegravir plus rilpivirine given by injection every 8 weeks appeared to be a promising new therapeutic option for people living with HIV at the 48-week mark in the ATLAS-2M trial.
Reuters Health Information